Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment

Höck, Christoph; Golombowski, Sidonie; Naser, W.; Müller‐Spahn, F.

doi:10.1002/ana.410370325

Cited by 79 publications

(29 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nor did we see an eff ect of time and APOE genotype on CSF tau protein levels. Th ese fi ndings concur with previous reports of CSF tau stability (including those from our laboratory) [4,8,9,19,21,22] , but disagree with a minority of studies that have shown either an increase in CSF tau protein over time [6,23] or an eff ect of APOE genotype on CSF tau levels [5][6][7]24] . It is notable that studies that have not observed tau stability have generally shown an increase in tau over time, which would not preclude its use as a diagnostic test over the course of the illness.…”

Section: Discussioncontrasting

confidence: 33%

Stability of CSF β-Amyloid<sub>1–42</sub> and Tau Levels by APOE Genotype in Alzheimer Patients

Huey¹,

Mirza²,

Putnam³

et al. 2006

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background: Cerebrospinal fluid (CSF) measures of β-amyloid_1–42and tau differ between patients with Alzheimer’s Disease (AD) and elderly normal controls. The effect of time and APOE genotype on these biomarkers continues to be elucidated. Methods: We assessed CSF β-amyloid_1–42 and tau in 20 mild-to-moderate AD patients, 11 APOE Ε4+ and 9 APOE Ε4–, over a mean time of 3.8 years (range 1–11.1 years). Results: Over the period measured, CSF β-amyloid_1–42 levels were lower in APOE Ε4+ compared to APOE Ε4– patients, and the levels decreased over time. Tau levels were stable over time and did not show an effect of APOE allele. Conclusions: While this is a limited clinical sample, the further decrease in CSF β-amyloid_1–42(i.e., more abnormal) combined with the CSF tau stability over a mean period of almost 4 years suggests that β-amyloid_1–42and tau maintain their potential usefulness as diagnostic biomarkers over time. These findings should be taken into account if CSF β-amyloid_1–42 and tau are used as measures of treatment response.

show abstract

Section: Discussioncontrasting

confidence: 33%

Stability of CSF β-Amyloid<sub>1–42</sub> and Tau Levels by APOE Genotype in Alzheimer Patients

Huey¹,

Mirza²,

Putnam³

et al. 2006

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…I). These findings were consistent with the previous report by Hock et al [3], which indicate a significant correla tion between the tau level in CSF and the severity of dementia.…”

supporting

confidence: 83%

“…Dear Madam, The measurement of tau protein (tau) in the cerebrospinal fluid (CSF) of Alzheimer's disease (AD) has recently been reported [1][2][3], Hock et al [3] reported that tau level in CSF increased in AD and indicated that tau level in CSF correlates with the degree of cognitive impairment. Their study was a cross-sectional design and could not discrim inate clearly the tau levels at different stages of AD.…”

mentioning

confidence: 99%

Tail Proteins in Cerebrospinal Fluid from Patients with Alzheimer's Disease: A Longitudinal Study

Isoe¹,

Urakami²,

Shimomura³

et al. 1996

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

“…Regarding the MMSE, results are contradictory. Some groups have shown a correlation between high tau and low MMSE scores in AD [4,6,14] while others did not [2,5,8,10,11,16,22,25]. The MMSE is a tool for estimation of cognitive status.…”

Section: Discussionmentioning

confidence: 99%

Cerebrospinal Fluid Tau Levels Increase with Age in Healthy Individuals

Blomberg

Jensen²,

Basun³

et al. 2001

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Cerebrospinal fluid (CSF) tau is a promising biochemical ante-mortem marker for Alzheimer’s disease (AD). Levels are increased in AD compared to other dementias, neurological diseases and healthy controls. An age-related decrease in both soluble tau and tau bound to paired helical filaments has been shown in brains from non-demented subjects. To study tau levels in normal ageing, we investigated CSF in 29 healthy individuals aged 45–80 years. A statistically significant increase in CSF tau with increasing age was found which might be caused by neuronal loss during normal ageing and redistribution of soluble tau from the brain into CSF. We could not demonstrate any influence by the APOE genotype, though larger populations have to be investigated to confirm this result. In conclusion, we found an age-dependent increase in CSF tau in healthy individuals. We emphasise the importance of establishing an age-dependent interval of CSF tau in non-demented subjects.

show abstract

Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment

Cited by 79 publications

References 4 publications

Stability of CSF β-Amyloid<sub>1–42</sub> and Tau Levels by APOE Genotype in Alzheimer Patients

Stability of CSF β-Amyloid<sub>1–42</sub> and Tau Levels by APOE Genotype in Alzheimer Patients

Tail Proteins in Cerebrospinal Fluid from Patients with Alzheimer's Disease: A Longitudinal Study

Cerebrospinal Fluid Tau Levels Increase with Age in Healthy Individuals

Contact Info

Product

Resources

About